Skip to content
You are now leaving to visit

Bench to bedside strategies demonstrate Ionis’ foremost expertise in RNA-targeted therapeutics at DIA/FDA Oligonucleotide Conference

– Ionis’ C. Frank Bennett, Ph.D., head of research, to give keynote address – 15 presentations highlighting the transformational potential of LICA medicines for a broad range of rare and common diseases CARLSBAD, Calif. , Oct. 28, 2019 /PRNewswire/ —  Ionis Pharmaceuticals, Inc.